Official ESCRS | European Society of Cataract & Refractive Surgeons
London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.

Neutralization of ocular surface TNF-alpha reduces ocular surface and lacrimal gland inflammation induced by in vivo dry eye

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Cornea Medical

Session Date/Time: Tuesday 16/09/2014 | 14:00-16:00

Paper Time: 14:24

Venue: Capital Hall A

First Author: : H.Lee SOUTH KOREA

Co Author(s): :    Y. Ji   W. Choi           

Abstract Details


The purpose of this study was to investigate the effectiveness of tumor necrosis factor (TNF)-alpha blocker for treatment of dry eye (DE)-induced inflammation and determine a more effective method to suppress lacrimal gland inflammation. Efficacy of topical versus systemic administration of TNF-alpha blockers was determined using a murine dry eye (DE) model.


Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea


The TNF-alpha blocker HL036 was developed by modification of the TNF receptor I. Protein purity, binding affinity, and clearance of TNF-alpha was compared with etanercept. Using DE-induced C57BL/6 mice, corneal erosion and goblet cell counts were measured after subcutaneous or topical treatment with etanercept or HL036. Inflammatory cytokines in cornea and lacrimal glands were determined by quantitative RT-PCR and ELISA.


HL036 showed TNF-alpha binding affinity comparable to etanercept, as measured by surface plasmon resonance. HL036 concentration was significantly higher in cornea and anterior segment than etanercept and effectively eliminated TNF-alpha on ocular surfaces. Etanercept was preferentially concentrated in the posterior segment. Corneal erosion and goblet cell counts were improved only with topically applied etanercept and HL036. Ocular surface IFN-gamma, IL-6, and IL-21 were significantly decreased by topical HL036. DE-induced lacrimal gland IFN-gamma and IL-6 expression was effectively suppressed by topical etanercept and HL036.


Topical TNF-alpha blockers effectively suppressed lacrimal gland and corneal inflammation by suppressing IFN-gamma, IL-21, and IL-6. Differences in TNF-alpha affinity, clearance, and local concentration of blockers may account for the anti-inflammatory effects in different ocular regions.

Financial Interest:


Back to previous